Medical Marijuana Shows Promise in Treating Symptoms of ALS

In a growing body of research and patient testimonials, medical marijuana is emerging as a potential treatment to alleviate the symptoms of Amyotrophic Lateral Sclerosis (ALS), a progressive and fatal neurodegenerative disease. Commonly known as Lou Gehrig’s disease, ALS affects nerve cells in the brain and spinal cord, gradually impairing voluntary muscle movement and leading to complete paralysis.

Although there is currently no cure for ALS, a number of studies and clinical observations suggest that medical cannabis may play a role in improving the quality of life for patients. The therapeutic properties of cannabinoids—particularly tetrahydrocannabinol (THC) and cannabidiol (CBD)—appear to help manage symptoms such as muscle spasticity, pain, appetite loss, and excessive saliva production.

A 2010 study published in the American Journal of Hospice and Palliative Medicine indicated that cannabis could significantly relieve a variety of ALS-related symptoms, including depression, drooling, and pain, with few adverse side effects (Amtmann et al., 2010). Another review in Neural Regeneration Research (2017) proposed that cannabinoids may have neuroprotective effects, potentially slowing the disease’s progression, although more clinical trials are needed to confirm this (Baker et al., 2017).

Additionally, a patient survey conducted by the ALS Association found that a growing number of individuals living with ALS are turning to cannabis to relieve symptoms, with many reporting improved sleep and reduced anxiety.

Despite the promising anecdotal and preliminary scientific evidence, medical marijuana remains federally illegal in the United States and is approved for ALS treatment only in select states. Advocates continue to push for broader research and federal rescheduling to facilitate clinical trials and improve patient access.

As scientific understanding evolves, medical cannabis may offer new hope for ALS patients seeking relief from one of the most devastating neurodegenerative conditions known today.

References:

Amtmann, D., Weydt, P., Johnson, K. L., Jensen, M. P., & Carter, G. T. (2010). Survey of cannabis use in patients with amyotrophic lateral sclerosis. American Journal of Hospice and Palliative Medicine®, 27(4), 347-349.

Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2017). The therapeutic potential of cannabis in the treatment of neurodegenerative diseases. Neural Regeneration Research, 12(5), 742–752.

ALS Association. (n.d.). Medical Marijuana and ALS. Retrieved from https://www.als.org

Dabbin-Dad Newsroom